Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Goodwill (2016 - 2023)

Coherus Oncology (CHRS) has disclosed Goodwill for 10 consecutive years, with $943000.0 as the latest value for Q4 2023.

  • Quarterly Goodwill changed 0.0% to $943000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $943000.0 through Dec 2023, changed 0.0% year-over-year, with the annual reading at $943000.0 for FY2023, 0.0% changed from the prior year.
  • Goodwill hit $943000.0 in Q4 2023 for Coherus Oncology, roughly flat from $943000.0 in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $943000.0 in Q1 2019 to a low of $900000.0 in Q4 2021.
  • Historically, Goodwill has averaged $940133.3 across 5 years, with a median of $943000.0 in 2019.
  • Biggest five-year swings in Goodwill: dropped 4.56% in 2021 and later grew 4.78% in 2022.
  • Year by year, Goodwill stood at $943000.0 in 2019, then changed by 0.0% to $943000.0 in 2020, then dropped by 4.56% to $900000.0 in 2021, then grew by 4.78% to $943000.0 in 2022, then changed by 0.0% to $943000.0 in 2023.
  • Business Quant data shows Goodwill for CHRS at $943000.0 in Q4 2023, $943000.0 in Q3 2023, and $943000.0 in Q4 2022.